FDA Approved: DOXORUBICIN HYDROCHLORIDE LIPOSOME — Supplemental Application (Baxter Healthcare Company)

View source ↗

Summary

FDA approved Baxter's supplemental NDA for doxorubicin hydrochloride liposome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aids-related Kaposi Sarcoma
• Kaposi Sarcoma
• Multiple Myeloma
• Ovarian Cancer

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE)

Snippet

SUPPL AP for DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE LIPOSOME)